Shares of GlaxoSmithKline plc (NYSE:GSK) have received a consensus rating of “Hold” from the eighteen brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $39.00.
A number of research analysts have recently issued reports on GSK shares. UBS Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Monday, January 15th. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Tuesday, January 9th. Argus reduced their price objective on GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a research report on Thursday, November 30th. TheStreet cut GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Finally, ValuEngine cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st.
Institutional investors and hedge funds have recently modified their holdings of the business. FinTrust Investment Advisory Services LLC purchased a new stake in GlaxoSmithKline in the third quarter worth about $401,000. Private Advisor Group LLC boosted its stake in GlaxoSmithKline by 7.2% during the third quarter. Private Advisor Group LLC now owns 77,976 shares of the pharmaceutical company’s stock valued at $3,166,000 after buying an additional 5,212 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its stake in GlaxoSmithKline by 110.3% during the third quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company’s stock valued at $356,000 after buying an additional 4,589 shares during the last quarter. Canandaigua National Bank & Trust Co. boosted its stake in GlaxoSmithKline by 14.6% during the fourth quarter. Canandaigua National Bank & Trust Co. now owns 15,297 shares of the pharmaceutical company’s stock valued at $543,000 after buying an additional 1,950 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in GlaxoSmithKline during the third quarter valued at approximately $1,209,000. Institutional investors and hedge funds own 9.17% of the company’s stock.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. The firm had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. equities analysts expect that GlaxoSmithKline will post 2.95 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Shareholders of record on Friday, February 23rd will be given a $0.633 dividend. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a yield of 7.01%. GlaxoSmithKline’s dividend payout ratio is presently 173.29%.
ILLEGAL ACTIVITY WARNING: “Analysts Set GlaxoSmithKline plc (GSK) Target Price at $39.00” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3230701/analysts-set-glaxosmithkline-plc-gsk-target-price-at-39-00.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.